A Pragmatic Approach to Managing Long-Term Adverse Effects in Chronic Myeloid Leukemia Treatment.
- Published in:
- Current Hematologic Malignancy Reports, 2023, v. 18, n. 4, p. 98, doi. 10.1007/s11899-023-00698-4
- By:
- Publication type:
- Article
Works matching IS 15588211 AND DT 2023 AND VI 18 AND IP 4
Results: 4
1
2
Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer.
- Published in:
- Current Hematologic Malignancy Reports, 2023, v. 18, n. 4, p. 105, doi. 10.1007/s11899-023-00697-5
- By:
- Publication type:
- Article
3
Pelabresib (CPI-0610): An Exciting Novel Drug for the Treatment of Myelofibrosis.
- Published in:
- Current Hematologic Malignancy Reports, 2023, v. 18, n. 4, p. 113, doi. 10.1007/s11899-023-00696-6
- By:
- Publication type:
- Article
4
GATA2 Deficiency: Predisposition to Myeloid Malignancy and Hematopoietic Cell Transplantation.
- Published in:
- Current Hematologic Malignancy Reports, 2023, v. 18, n. 4, p. 89, doi. 10.1007/s11899-023-00695-7
- By:
- Publication type:
- Article